Literature DB >> 24435445

Targeting microtubules by natural agents for cancer therapy.

Eiman Mukhtar1, Vaqar Mustafa Adhami, Hasan Mukhtar.   

Abstract

Natural compounds that target microtubules and disrupt the normal function of the mitotic spindle have proven to be one of the best classes of cancer chemotherapeutic drugs available in clinics to date. There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell-cycle progression at mitosis and subsequently leading to cell death. Our improved understanding of tumor biology and our continued appreciation for what the microtubule targeting agents (MTAs) can do have helped pave the way for a new era in the treatment of cancer. The effectiveness of these agents for cancer therapy has been impaired, however, by various side effects and drug resistance. Several new MTAs have shown potent activity against the proliferation of various cancer cells, including resistance to the existing MTAs. Sustained investigation of the mechanisms of action of MTAs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance could provide more effective therapeutic options for patients with cancer. This review focuses on the successful cancer chemotherapy from natural compounds in clinical settings and the challenges that may abort their usefulness.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24435445      PMCID: PMC3946048          DOI: 10.1158/1535-7163.MCT-13-0791

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  75 in total

1.  Cell cycle-dependent changes in microtubule dynamics in living cells expressing green fluorescent protein-alpha tubulin.

Authors:  N M Rusan; C J Fagerstrom; A M Yvon; P Wadsworth
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

2.  Do beta-tubulin pseudogenes really matter?

Authors:  Cristobal Belda-Iniesta; Rosario Perona; Javier de Castro Carpeno; Sharmila Chattopadhyay; Enrique Casado; Paloma Cejas; Juan Angel Fresno Vara; Concepcion Moreno Guerra; Manuel Gonzalez Baron
Journal:  Lancet Oncol       Date:  2004-05       Impact factor: 41.316

3.  Structural basis of the activity of the microtubule-stabilizing agent epothilone a studied by NMR spectroscopy in solution.

Authors:  Marcel Reese; Víctor M Sánchez-Pedregal; Karel Kubicek; Jens Meiler; Marcel J J Blommers; Christian Griesinger; Teresa Carlomagno
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

Review 4.  Microtubule dynamics and kinetochore function in mitosis.

Authors:  T J Mitchison
Journal:  Annu Rev Cell Biol       Date:  1988

Review 5.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

Review 6.  Anticancer therapy with novel tubulin-interacting drugs.

Authors:  M Kavallaris; N M Verrills; B T Hill
Journal:  Drug Resist Updat       Date:  2001-12       Impact factor: 18.500

Review 7.  The management of gout.

Authors:  B T Emmerson
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

8.  Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations.

Authors:  M Monzó; R Rosell; J J Sánchez; J S Lee; A O'Brate; J L González-Larriba; V Alberola; J C Lorenzo; L Núñez; J Y Ro; C Martín
Journal:  J Clin Oncol       Date:  1999-06       Impact factor: 44.544

9.  Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma.

Authors:  Qian Zhou; Arthur K-K Ching; Wilson K-C Leung; Carol Y-Y Szeto; Shuk-Mei Ho; Paul K-S Chan; Yun-Fei Yuan; Paul B-S Lai; Winnie Yeo; Nathalie Wong
Journal:  Int J Oncol       Date:  2011-01-14       Impact factor: 5.650

10.  Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.

Authors:  Tomasz M Beer; Celestia S Higano; Mansoor Saleh; Robert Dreicer; Gary Hudes; Joel Picus; Mark Rarick; Louis Fehrenbacher; Alison L Hannah
Journal:  Invest New Drugs       Date:  2007-07-07       Impact factor: 3.850

View more
  129 in total

Review 1.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

2.  Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule targeting agent.

Authors:  Weiguo Xiang; Shruti Choudhary; Ernest Hamel; Susan L Mooberry; Aleem Gangjee
Journal:  Bioorg Med Chem       Date:  2018-04-04       Impact factor: 3.641

3.  The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines.

Authors:  Taryn E Dick; Jeremy A Hengst; Todd E Fox; Ashley L Colledge; Vijay P Kale; Shen-Shu Sung; Arun Sharma; Shantu Amin; Thomas P Loughran; Mark Kester; Hong-Gang Wang; Jong K Yun
Journal:  J Pharmacol Exp Ther       Date:  2015-01-06       Impact factor: 4.030

4.  Harnessing the Potential Synergistic Interplay Between Photosensitizer Dark Toxicity and Chemotherapy.

Authors:  Yan Baglo; Aaron J Sorrin; Barry J Liang; Huang-Chiao Huang
Journal:  Photochem Photobiol       Date:  2020-02-16       Impact factor: 3.421

Review 5.  Molecular Pathways: New Signaling Considerations When Targeting Cytoskeletal Balance to Reduce Tumor Growth.

Authors:  Kristi R Chakrabarti; Lindsay Hessler; Lekhana Bhandary; Stuart S Martin
Journal:  Clin Cancer Res       Date:  2015-10-13       Impact factor: 12.531

6.  2-Alkoxycarbonyl-3-arylamino-5-substituted thiophenes as a novel class of antimicrotubule agents: Design, synthesis, cell growth and tubulin polymerization inhibition.

Authors:  Romeo Romagnoli; Maria Kimatrai Salvador; Santiago Schiaffino Ortega; Pier Giovanni Baraldi; Paola Oliva; Stefania Baraldi; Luisa Carlota Lopez-Cara; Andrea Brancale; Salvatore Ferla; Ernest Hamel; Jan Balzarini; Sandra Liekens; Elena Mattiuzzo; Giuseppe Basso; Giampietro Viola
Journal:  Eur J Med Chem       Date:  2018-01-01       Impact factor: 6.514

7.  First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.

Authors:  Elena Elez; Carlos Gomez-Roca; Arturo Soto Matos-Pita; Guillem Argiles; Thibaud Valentin; Cinthya Coronado; Jorge Iglesias; Teresa Macarulla; Sarah Betrian; Salvador Fudio; Katrin Zaragoza; Josep Tabernero; Jean-Pierre Delord
Journal:  Invest New Drugs       Date:  2018-11-09       Impact factor: 3.850

8.  An unusual gastric biopsy.

Authors:  Dmitry Zinovkin; Mikhail Zhandarov; Elizaveta Bredyhina; Md Zahidul Islam Pranjol
Journal:  Turk J Gastroenterol       Date:  2020-01       Impact factor: 1.852

Review 9.  Microtubule destabilising agents: far more than just antimitotic anticancer drugs.

Authors:  Darcy Bates; Alan Eastman
Journal:  Br J Clin Pharmacol       Date:  2016-10-18       Impact factor: 4.335

10.  Synthesis and biological evaluation of isomeric methoxy substitutions on anti-cancer indolyl-pyridinyl-propenones: Effects on potency and mode of activity.

Authors:  Christopher J Trabbic; Sage M George; Evan M Alexander; Shengnan Du; Jennifer M Offenbacher; Emily J Crissman; Jean H Overmeyer; William A Maltese; Paul W Erhardt
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.